CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 5.4%

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s stock price traded down 5.4% during mid-day trading on Wednesday . The stock traded as low as $60.31 and last traded at $61.69. 842,038 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 1,875,040 shares. The stock had previously closed at $65.19.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Barclays upped their target price on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 22nd. Royal Bank of Canada boosted their price target on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 22nd. Morgan Stanley boosted their price target on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an "underweight" rating in a research note on Monday, February 26th. Wells Fargo & Company boosted their price target on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 22nd. Finally, Chardan Capital increased their target price on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a "buy" rating in a report on Thursday, February 22nd. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $74.75.

CRISPR Therapeutics Price Performance

The company has a market capitalization of $4.96 billion, a P/E ratio of -31.50 and a beta of 1.76. The stock's 50 day moving average is $74.12 and its 200-day moving average is $62.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, beating analysts' consensus estimates of $0.15 by $0.95. The business had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. During the same period in the prior year, the business posted ($1.41) EPS. CRISPR Therapeutics's revenue for the quarter was up 3253.3% on a year-over-year basis. On average, equities research analysts anticipate that CRISPR Therapeutics AG will post -6.24 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,000 shares of the firm's stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the completion of the transaction, the chief executive officer now owns 187,377 shares of the company's stock, valued at $11,338,182.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Samarth Kulkarni sold 50,000 shares of the firm's stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the completion of the sale, the chief executive officer now owns 187,377 shares of the company's stock, valued at $11,338,182.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Raju Prasad sold 3,524 shares of the firm's stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.69, for a total transaction of $256,159.56. Following the sale, the chief financial officer now directly owns 6,476 shares of the company's stock, valued at approximately $470,740.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 134,410 shares of company stock valued at $9,234,677. Corporate insiders own 4.10% of the company's stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC boosted its holdings in CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company's stock worth $26,000 after purchasing an additional 260 shares during the last quarter. Tradewinds Capital Management LLC boosted its holdings in CRISPR Therapeutics by 545.5% in the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company's stock worth $32,000 after purchasing an additional 600 shares during the last quarter. Blue Trust Inc. purchased a new stake in CRISPR Therapeutics in the fourth quarter worth approximately $32,000. Headlands Technologies LLC purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter worth $34,000. Finally, Bourgeon Capital Management LLC boosted its stake in shares of CRISPR Therapeutics by 1,000.0% during the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company's stock worth $34,000 after acquiring an additional 500 shares during the last quarter. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.